Skip to main content
. Author manuscript; available in PMC: 2012 Nov 1.
Published in final edited form as: Cancer Prev Res (Phila). 2011 Aug 16;4(11):1938–1944. doi: 10.1158/1940-6207.CAPR-10-0259

Table 3.

Pharmacokinetic parameter estimates

Cmax (ng/ml) AUC (ng*hr/ml)
(a) Placebo
Mean (sd) 10.0 (1.00) < 0 (x)
Median 10.0 < 0
CV % 10.0 -
(b) 400 mcg
Mean (sd) 22.8 (9.9) 427.1 (276.5)
Median 21.0 435.5
95 % CI (-25.5, 51.1) (-79.6, 934.0)
(c) 800 mcg
Mean (sd) 30.75 (8.4) 567.5 (243.0)*
Median 30.5 648.75
95 % CI (-19.3, 60.8) (37.6, 1100)
(d) 1200 mcg
Mean (sd) 63.2 (27.8)* 1077.9 (203.3)*
Median 57.0 1055.3
95% CI (14.9-91.5) (571, 1580)

Note:

*

P < .05: determined by comparison of each dose group (400mcg, 800mcg, and 1200mcg) to placebo group.